Shenzhen Neptunus Bioengineering Co., Ltd. Logo

Shenzhen Neptunus Bioengineering Co., Ltd.

000078.SZ

(0.8)
Stock Price

2,45 CNY

-5.69% ROA

-49.97% ROE

-4.12x PER

Market Cap.

6.437.377.669,00 CNY

362.82% DER

0% Yield

-5.23% NPM

Shenzhen Neptunus Bioengineering Co., Ltd. Stock Analysis

Shenzhen Neptunus Bioengineering Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Shenzhen Neptunus Bioengineering Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's PBV ratio (1.79x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

2 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

3 Buffet Intrinsic Value

The company's stock seems undervalued (311) by Warren Buffett's formula, indicating a promising investment opportunity as its intrinsic value exceeds the market price.

4 ROE

The stock's ROE indicates a negative return (-18.44%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-2.85%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 DER

The company has a high debt to equity ratio (264%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

7 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

9 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

10 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

11 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

Shenzhen Neptunus Bioengineering Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Shenzhen Neptunus Bioengineering Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Shenzhen Neptunus Bioengineering Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Shenzhen Neptunus Bioengineering Co., Ltd. Revenue
Year Revenue Growth
1995 49.824.557
1996 77.828.998 35.98%
1997 62.673.289 -24.18%
1998 64.476.697 2.8%
1999 88.391.743 27.06%
2000 198.977.073 55.58%
2001 765.051.545 73.99%
2002 829.427.619 7.76%
2003 1.281.647.578 35.28%
2004 2.321.947.095 44.8%
2005 2.657.991.886 12.64%
2006 2.690.784.500 1.22%
2007 2.495.001.667 -7.85%
2008 2.211.799.530 -12.8%
2009 2.710.042.867 18.39%
2010 3.999.052.353 32.23%
2011 5.305.028.948 24.62%
2012 6.418.021.706 17.34%
2013 7.993.433.971 19.71%
2014 9.802.350.831 18.45%
2015 11.117.734.985 11.83%
2016 13.605.921.667 18.29%
2017 24.939.637.653 45.44%
2018 38.380.907.262 35.02%
2019 41.492.703.945 7.5%
2020 40.022.495.409 -3.67%
2021 41.053.584.128 2.51%
2022 37.834.858.745 -8.51%
2023 34.746.344.748 -8.89%
2023 36.418.770.306 4.59%
2024 34.174.006.836 -6.57%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Shenzhen Neptunus Bioengineering Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
1995 0
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 18.175.777 100%
2011 22.361.979 18.72%
2012 42.232.326 47.05%
2013 45.891.208 7.97%
2014 44.741.707 -2.57%
2015 50.610.001 11.6%
2016 40.140.060 -26.08%
2017 101.092.246 60.29%
2018 44.847.510 -125.41%
2019 42.191.099 -6.3%
2020 38.167.121 -10.54%
2021 39.226.809 2.7%
2022 48.433.791 19.01%
2023 56.428.316 14.17%
2023 47.938.144 -17.71%
2024 45.623.328 -5.07%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Shenzhen Neptunus Bioengineering Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
1995 17.948.068
1996 38.415.845 53.28%
1997 10.782.696 -256.27%
1998 8.930.863 -20.74%
1999 11.612.263 23.09%
2000 31.188.188 62.77%
2001 95.638.944 67.39%
2002 136.629.709 30%
2003 157.530.587 13.27%
2004 74.566.735 -111.26%
2005 446.541.543 83.3%
2006 200.070.034 -123.19%
2007 156.973.276 -27.45%
2008 150.788.852 -4.1%
2009 166.296.315 9.33%
2010 98.595.519 -68.67%
2011 102.670.990 3.97%
2012 121.518.376 15.51%
2013 128.922.997 5.74%
2014 137.216.274 6.04%
2015 126.494.777 -8.48%
2016 118.648.505 -6.61%
2017 215.882.330 45.04%
2018 566.165.068 61.87%
2019 557.178.655 -1.61%
2020 456.984.389 -21.93%
2021 410.465.934 -11.33%
2022 400.584.470 -2.47%
2023 2.636.168.455 84.8%
2023 367.562.678 -617.2%
2024 -283.358.734 229.72%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Shenzhen Neptunus Bioengineering Co., Ltd. EBITDA
Year EBITDA Growth
1995 10.994.687
1996 19.225.061 42.81%
1997 20.168.369 4.68%
1998 29.446.353 31.51%
1999 39.676.986 25.78%
2000 129.831.589 69.44%
2001 176.225.515 26.33%
2002 142.860.189 -23.36%
2003 -100.043.792 242.8%
2004 144.989.774 169%
2005 -600.470.636 124.15%
2006 168.756.815 455.82%
2007 226.426.177 25.47%
2008 162.911.894 -38.99%
2009 146.273.758 -11.37%
2010 266.094.938 45.03%
2011 293.575.420 9.36%
2012 331.926.805 11.55%
2013 600.869.096 44.76%
2014 450.030.971 -33.52%
2015 995.878.112 54.81%
2016 940.428.600 -5.9%
2017 1.632.155.690 42.38%
2018 2.443.827.268 33.21%
2019 2.705.316.574 9.67%
2020 2.110.487.204 -28.18%
2021 1.998.046.920 -5.63%
2022 1.228.514.501 -62.64%
2023 1.008.155.538 -21.86%
2023 1.158.041.629 12.94%
2024 937.330.516 -23.55%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Shenzhen Neptunus Bioengineering Co., Ltd. Gross Profit
Year Gross Profit Growth
1995 29.224.245
1996 58.188.955 49.78%
1997 47.128.750 -23.47%
1998 48.046.952 1.91%
1999 68.428.715 29.79%
2000 157.110.082 56.45%
2001 530.044.775 70.36%
2002 598.126.877 11.38%
2003 357.392.210 -67.36%
2004 475.797.752 24.89%
2005 247.163.583 -92.5%
2006 361.603.650 31.65%
2007 351.566.560 -2.85%
2008 350.147.702 -0.41%
2009 466.311.612 24.91%
2010 656.992.734 29.02%
2011 880.841.389 25.41%
2012 970.056.837 9.2%
2013 1.210.491.777 19.86%
2014 1.430.619.901 15.39%
2015 1.628.243.007 12.14%
2016 2.023.654.948 19.54%
2017 3.595.498.586 43.72%
2018 5.040.791.179 28.67%
2019 5.520.818.841 8.69%
2020 4.647.239.560 -18.8%
2021 4.398.090.174 -5.66%
2022 3.789.823.622 -16.05%
2023 3.464.729.022 -9.38%
2023 3.553.325.097 2.49%
2024 3.320.634.456 -7.01%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Shenzhen Neptunus Bioengineering Co., Ltd. Net Profit
Year Net Profit Growth
1995 11.371.848
1996 17.005.261 33.13%
1997 18.157.260 6.34%
1998 26.149.850 30.56%
1999 31.066.997 15.83%
2000 61.533.530 49.51%
2001 79.819.022 22.91%
2002 42.227.035 -89.02%
2003 -219.955.184 119.2%
2004 22.070.214 1096.62%
2005 -741.886.188 102.97%
2006 42.470.248 1846.84%
2007 38.680.460 -9.8%
2008 24.303.604 -59.16%
2009 14.158.967 -71.65%
2010 46.668.563 69.66%
2011 52.528.359 11.16%
2012 59.066.952 11.07%
2013 117.047.963 49.54%
2014 23.791.540 -391.97%
2015 474.732.125 94.99%
2016 418.395.707 -13.46%
2017 639.190.547 34.54%
2018 448.205.940 -42.61%
2019 514.901.772 12.95%
2020 -41.287.960 1347.1%
2021 257.867.596 116.01%
2022 -992.131.349 125.99%
2023 3.213.407 30974.76%
2023 -1.689.944.687 100.19%
2024 11.073.620 15361%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Shenzhen Neptunus Bioengineering Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1995 0
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 1 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 -1 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Shenzhen Neptunus Bioengineering Co., Ltd. Free Cashflow
Year Free Cashflow Growth
1998 -44.319.285
1999 -50.085.895 11.51%
2000 -147.247.803 65.99%
2001 -272.836.425 46.03%
2002 -164.695.849 -65.66%
2003 -151.119.502 -8.98%
2004 -204.757.549 26.2%
2005 -153.611.447 -33.3%
2006 -94.188.636 -63.09%
2007 -45.853.943 -105.41%
2008 148.198.490 130.94%
2009 76.311.323 -94.2%
2010 -70.001.095 209.01%
2011 -290.434.215 75.9%
2012 -241.530.893 -20.25%
2013 -408.848.438 40.92%
2014 -354.072.186 -15.47%
2015 -79.747.606 -343.99%
2016 -1.780.053.694 95.52%
2017 -2.705.458.074 34.21%
2018 -1.348.685.663 -100.6%
2019 2.101.089.388 164.19%
2020 1.503.262.159 -39.77%
2021 736.894.412 -104%
2022 -158.646.985 564.49%
2023 -65.374.627 -142.67%
2023 -514.263.894 87.29%
2024 25.664.075 2103.83%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Shenzhen Neptunus Bioengineering Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
1998 -38.127.732
1999 -20.126.083 -89.44%
2000 -109.251.205 81.58%
2001 -82.836.672 -31.89%
2002 -111.825.003 25.92%
2003 -28.439.649 -293.2%
2004 -61.339.099 53.64%
2005 35.824.616 271.22%
2006 54.041.409 33.71%
2007 50.586.344 -6.83%
2008 205.386.434 75.37%
2009 206.344.074 0.46%
2010 40.956.744 -403.81%
2011 -190.334.820 121.52%
2012 -81.725.560 -132.9%
2013 -123.071.951 33.6%
2014 -117.480.859 -4.76%
2015 90.507.110 229.8%
2016 -1.496.994.920 106.05%
2017 -2.432.914.043 38.47%
2018 -1.135.175.523 -114.32%
2019 2.268.621.934 150.04%
2020 1.650.554.959 -37.45%
2021 866.120.634 -90.57%
2022 -64.328.676 1446.4%
2023 -41.628.381 -54.53%
2023 -410.189.288 89.85%
2024 60.182.779 781.57%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Shenzhen Neptunus Bioengineering Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
1998 6.191.553
1999 29.959.812 79.33%
2000 37.996.598 21.15%
2001 189.999.753 80%
2002 52.870.846 -259.37%
2003 122.679.854 56.9%
2004 143.418.451 14.46%
2005 189.436.063 24.29%
2006 148.230.045 -27.8%
2007 96.440.287 -53.7%
2008 57.187.944 -68.64%
2009 130.032.750 56.02%
2010 110.957.839 -17.19%
2011 100.099.396 -10.85%
2012 159.805.333 37.36%
2013 285.776.486 44.08%
2014 236.591.327 -20.79%
2015 170.254.716 -38.96%
2016 283.058.773 39.85%
2017 272.544.031 -3.86%
2018 213.510.140 -27.65%
2019 167.532.546 -27.44%
2020 147.292.800 -13.74%
2021 129.226.221 -13.98%
2022 94.318.309 -37.01%
2023 23.746.246 -297.19%
2023 104.074.606 77.18%
2024 34.518.704 -201.5%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Shenzhen Neptunus Bioengineering Co., Ltd. Equity
Year Equity Growth
1995 52.153.740
1996 56.144.924 7.11%
1997 57.626.756 2.57%
1998 177.076.418 67.46%
1999 205.688.849 13.91%
2000 238.747.751 13.85%
2001 1.974.770.460 87.91%
2002 2.063.193.367 4.29%
2003 1.443.413.144 -42.94%
2004 1.451.963.933 0.59%
2005 805.257.680 -80.31%
2006 868.759.422 7.31%
2007 903.623.121 3.86%
2008 780.787.236 -15.73%
2009 692.585.847 -12.74%
2010 902.622.865 23.27%
2011 971.039.713 7.05%
2012 1.056.977.946 8.13%
2013 1.888.007.374 44.02%
2014 1.782.576.730 -5.91%
2015 2.143.062.053 16.82%
2016 5.877.961.514 63.54%
2017 6.469.997.280 9.15%
2018 7.158.345.029 9.62%
2019 7.850.702.866 8.82%
2020 7.489.795.313 -4.82%
2021 7.308.258.475 -2.48%
2022 6.110.430.727 -19.6%
2023 6.186.194.471 1.22%
2023 4.217.445.261 -46.68%
2024 4.249.652.214 0.76%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Shenzhen Neptunus Bioengineering Co., Ltd. Assets
Year Assets Growth
1995 82.527.632
1996 123.001.412 32.91%
1997 145.625.794 15.54%
1998 229.965.314 36.67%
1999 642.281.207 64.2%
2000 872.297.171 26.37%
2001 3.043.626.975 71.34%
2002 3.429.311.783 11.25%
2003 4.029.470.349 14.89%
2004 3.727.844.029 -8.09%
2005 3.986.122.448 6.48%
2006 3.522.390.456 -13.17%
2007 3.121.599.034 -12.84%
2008 2.777.538.083 -12.39%
2009 3.164.752.975 12.24%
2010 4.147.788.796 23.7%
2011 4.835.321.705 14.22%
2012 5.863.516.482 17.54%
2013 8.019.242.139 26.88%
2014 9.631.706.545 16.74%
2015 12.762.259.215 24.53%
2016 16.661.466.476 23.4%
2017 30.864.382.532 46.02%
2018 41.126.743.376 24.95%
2019 41.168.283.718 0.1%
2020 39.720.506.526 -3.64%
2021 37.603.849.419 -5.63%
2022 36.252.275.970 -3.73%
2023 36.011.587.264 -0.67%
2023 32.304.686.545 -11.47%
2024 31.759.675.399 -1.72%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Shenzhen Neptunus Bioengineering Co., Ltd. Liabilities
Year Liabilities Growth
1995 30.373.891
1996 66.856.487 54.57%
1997 87.999.037 24.03%
1998 52.888.894 -66.38%
1999 436.592.357 87.89%
2000 633.549.419 31.09%
2001 1.068.856.514 40.73%
2002 1.366.118.415 21.76%
2003 2.586.057.204 47.17%
2004 2.275.880.096 -13.63%
2005 3.180.864.766 28.45%
2006 2.653.631.032 -19.87%
2007 2.217.975.912 -19.64%
2008 1.996.750.846 -11.08%
2009 2.472.167.128 19.23%
2010 3.245.165.931 23.82%
2011 3.864.281.991 16.02%
2012 4.806.538.535 19.6%
2013 6.131.234.764 21.61%
2014 7.849.129.815 21.89%
2015 10.619.197.161 26.09%
2016 10.783.504.961 1.52%
2017 24.394.385.250 55.8%
2018 33.968.398.346 28.19%
2019 33.317.580.851 -1.95%
2020 32.230.711.212 -3.37%
2021 30.295.590.943 -6.39%
2022 30.141.845.242 -0.51%
2023 29.825.392.793 -1.06%
2023 28.087.241.284 -6.19%
2024 27.510.023.184 -2.1%

Shenzhen Neptunus Bioengineering Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
12.57
Net Income per Share
-0.66
Price to Earning Ratio
-4.12x
Price To Sales Ratio
0.19x
POCF Ratio
-13.99
PFCF Ratio
-10.35
Price to Book Ratio
2.34
EV to Sales
0.41
EV Over EBITDA
19.66
EV to Operating CashFlow
-26.48
EV to FreeCashFlow
-21.71
Earnings Yield
-0.24
FreeCashFlow Yield
-0.1
Market Cap
6,44 Bil.
Enterprise Value
13,50 Bil.
Graham Number
4.14
Graham NetNet
-2.44

Income Statement Metrics

Net Income per Share
-0.66
Income Quality
0.29
ROE
-0.5
Return On Assets
-0.05
Return On Capital Employed
-0.33
Net Income per EBT
1.14
EBT Per Ebit
1
Ebit per Revenue
-0.05
Effective Tax Rate
-0.16

Margins

Sales, General, & Administrative to Revenue
0.01
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.09
Operating Profit Margin
-0.05
Pretax Profit Margin
-0.05
Net Profit Margin
-0.05

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0.3
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.19
Free CashFlow per Share
-0.24
Capex to Operating CashFlow
-0.22
Capex to Revenue
0
Capex to Depreciation
0.39
Return on Invested Capital
-0.13
Return on Tangible Assets
-0.06
Days Sales Outstanding
223.77
Days Payables Outstanding
122.3
Days of Inventory on Hand
42.62
Receivables Turnover
1.63
Payables Turnover
2.98
Inventory Turnover
8.56
Capex per Share
0.04

Balance Sheet

Cash per Share
1,57
Book Value per Share
1,61
Tangible Book Value per Share
1.11
Shareholders Equity per Share
1.16
Interest Debt per Share
4.54
Debt to Equity
3.63
Debt to Assets
0.35
Net Debt to EBITDA
10.29
Current Ratio
1.04
Tangible Asset Value
2,92 Bil.
Net Current Asset Value
0,74 Bil.
Invested Capital
3751292904
Working Capital
1,16 Bil.
Intangibles to Total Assets
0.04
Average Receivables
19,55 Bil.
Average Payables
10,23 Bil.
Average Inventory
3481642112
Debt to Market Cap
1.72

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Shenzhen Neptunus Bioengineering Co., Ltd. Dividends
Year Dividends Growth
1999 0
2001 0 0%
2018 0 0%
2019 0 0%

Shenzhen Neptunus Bioengineering Co., Ltd. Profile

About Shenzhen Neptunus Bioengineering Co., Ltd.

Shenzhen Neptunus Bioengineering Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products primarily in China. It offers drugs in the fields of anti-tumor, cardio-cerebrovascular, marine drugs, and other fields. The company was founded in 1989 and is based in Shenzhen, China.

CEO
Mr. Feng Zhang
Employee
9.093
Address
Wang Yinhe Technology Building
Shenzhen, 518057

Shenzhen Neptunus Bioengineering Co., Ltd. Executives & BODs

Shenzhen Neptunus Bioengineering Co., Ltd. Executives & BODs
# Name Age
1 Mr. Feng Zhang
Vice Chairman of the Board & President
70
2 Mr. Da Kai Shen
Financial Director, Vice President & Director
70
3 Mr. Rui Jin
Vice President & Non-Independent Director
70
4 Mr. Xiao Peng Wang
Vice President
70
5 Mr. Shuangcheng Yang
Vice President
70
6 Mr. Xiaoming Shi
Vice President
70
7 Mr. Yi Fei Zhang
Executive Vice President & Director
70
8 Mr. Yunlei Wang
Vice President & Board Secretary
70
9 Mr. Ge Jin
Vice President
70

Shenzhen Neptunus Bioengineering Co., Ltd. Competitors